Opus Genetics (IRD) to Release Earnings on Thursday

Opus Genetics (NASDAQ:IRD) is expected to be releasing its earnings data on Thursday, March 6th. Analysts expect Opus Genetics to post earnings of ($0.02) per share and revenue of $11.10 million for the quarter.

Opus Genetics Trading Down 5.7 %

Shares of NASDAQ IRD opened at $0.97 on Tuesday. The business’s 50-day moving average is $1.16. Opus Genetics has a 1-year low of $0.81 and a 1-year high of $2.51. The stock has a market cap of $30.68 million, a P/E ratio of -0.89 and a beta of 0.16.

Insider Activity

In other Opus Genetics news, CEO George Magrath acquired 100,000 shares of the company’s stock in a transaction dated Thursday, December 26th. The shares were acquired at an average price of $0.98 per share, for a total transaction of $98,000.00. Following the acquisition, the chief executive officer now owns 599,150 shares in the company, valued at $587,167. The trade was a 20.03 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 6.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Opus Genetics in a report on Wednesday, February 19th.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.